FY2025 EPS Estimates for Codexis Cut by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS) – Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Codexis in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of ($0.62) per share for the year, down from their prior estimate of ($0.60). The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $7.54 million for the quarter, compared to analysts’ expectations of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%.

Separately, StockNews.com upgraded shares of Codexis to a “sell” rating in a research report on Friday.

Codexis Stock Performance

NASDAQ CDXS opened at $2.47 on Monday. The company has a fifty day moving average of $2.44 and a two-hundred day moving average of $3.74. The company has a market capitalization of $204.63 million, a PE ratio of -2.84 and a beta of 2.56. Codexis has a 1 year low of $1.90 and a 1 year high of $6.08. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15.

Hedge Funds Weigh In On Codexis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. boosted its position in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock worth $40,000 after buying an additional 3,783 shares in the last quarter. Wolverine Trading LLC acquired a new position in Codexis during the fourth quarter worth about $56,000. Fiduciary Trust Co purchased a new stake in shares of Codexis in the fourth quarter valued at about $65,000. Group One Trading LLC acquired a new stake in shares of Codexis in the fourth quarter valued at approximately $73,000. Finally, Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis in the fourth quarter valued at approximately $79,000. 78.54% of the stock is owned by institutional investors and hedge funds.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.